ISSN 1300-4948 | E-ISSN 2148-5607
Review
Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?
Turk J Gastroenterol 2017; 28: 31-32
DOI: 10.5152/tjg.2017.09
This article was viewed 0 times, downloaded 1 times

Key Words: Barrett's esophagus, proton pump inhibitors, adenocarcinoma
Abstract

Besides reducing the reflux symptoms, the benefit of proton pump inhibitors (PPI) in the treatment of Barrett's esophagus (BE) is not exactly known. The data in the literature show that although the PPI treatment does not reduce the Barrett's segment length, it can reduce dysplasia or the development of early-stage adenocarcinoma (odds ratio (OR): 0.46). Therefore, treatments with PPI may be considered in patients with a diagnosis of BE and at a high risk of adenocarcinoma, even though they are not symptomatic.

 

 

Cite this article as: Akın H, Aydın Y. Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus? Turk J Gastroenterol 2017;28(Suppl 1); S31-S32

 

Full Text Turkish

Key Words
Authors
All
Reviewer's Corner
Author’s Corner
Survey
AVES | Copyright © 2017 Turkish Society of Gastroenterology | Latest Update: 30.11.2017